Bioinformatics applications in the detection of biomarkers and drug targetsin colorectal cancer

Abstract

Colorectal cancer (CRC) remains a significant global health challenge, necessitating innovative therapeutic strategies. Bioinformatics offers a powerful tool to
unravel the complex molecular underpinnings of CRC, enabling the discovery of novel biomarkers and therapeutic targets. This review explores the application of bioinformatics in CRC research, with a focus on leveraging large-scale genomic and clinical data. We discuss the integration of artificial intelligence and machine learning to enhance biomarker identification, drug discovery, and patient stratification. While bioinformatics has shown immense potential, challenges such as data quality, privacy, and computational resources need to be addressed. Overcoming these hurdles is crucial for translating bioinformatics insights into clinical practice and improving patient outcomes. Ultimately, this review emphasizes the transformative role of bioinformatics in precision medicine for CRC.

Keywords

Introduction

Colorectal cancer (CRC) is a significant public health concern, ranking as the third most common cancer worldwide ¹. Despite advancements in diagnostic and therapeutic methods, a steady increase in colorectal cancer incidence and mortality has been observed in Europe, underscoring the need for further progress in non-invasive diagnostic techniques to enable early diagnosis, pre-and postoperative staging, and to assist in selecting the most suitable neo-adjuvant and adjuvant therapeutic methods and post-treatment follow-up ².
Bioinformatics techniques have emerged as an important means to identify the most original and causative biomarkers for individualized cancer chemotherapy ³. The application of advanced bioinformatics tools, such as machine learning algorithms and network analysis, has enabled the discovery of novel biomarker candidates that can serve as more accurate and reliable indicators of colorectal cancer risk, prognosis, and treatment response. These computational approaches have the potential to uncover complex molecular alterations and signaling pathways that drive colorectal tumorigenesis, ultimately informing the development of targeted therapies and personalized treatment strategies [4–6].Progress and Development in CRC TreatmentColorectal cancer is the third most prevalent malignant tumor worldwide and the second most lethal cancer ⁷. In 2018, 1.8 million new CRC cases were reported, and 881,000 deaths were recorded, accounting for nearly 10% of new cancer cases and deaths globally ⁷. Approximately 80%-90% of metastatic CRC patients have been determined to have unresectable disease, and the median overall survival is estimated to be around 30 months ⁸.
To address this challenge, researchers have been exploring various immunotherapy approaches, including checkpoint inhibitors, cancer vaccines, and adoptive cell therapy ⁸. Checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 antibodies, have demonstrated significant clinical benefits in a subset of CRC patients with high microatoll instability or mismatch repair- deficient (dMMR) tumours ^8,9. These therapies have been shown to elicit durable responses and improve overall survival in these patient populations. In addition to immunotherapy, the development of various targeted therapies, such as anti- angiogenic agents ¹⁰, EGFR inhibitors, and BRAF inhibitors, has also contributed significantly to the progress in CRC treatment ¹¹. These targeted therapies have shown improved outcomes, including prolonged progression-free and overall survival, in specific molecular subtypes of colorectal cancer ⁷. While these advancements have been promising, the prognosis for patients with metastatic CRC remains poor, with a 5-year survival rate of only 12.5% in the United States ⁹. Therefore, the continued development of more effective treatments, including combination therapies and novel targeted agents, is an urgent unmet need to further improve the outcomes for CRC patients.Targeted TherapiesTargeted therapies are also being developed, such as cetuximab which targets the epidermal growth factor receptor and results in more positive responses and secondary bevacizumab, which essentially inhibits vascular endothelial growth factors ¹².
Recently, immunotherapy has been developed as a promising strategy for the treatment of CRC tumors characterized by high microsatellite instability, repair failure, and immunosuppressive agents (pembrolizumab and nivolumab). Other than this, somatic variations have the potential to encode “non-self” immunogenic antigens. It is verified that tumors with a large number of somatic alterations due to mismatch-repair faults may be vulnerable to immune checkpoint blockade ¹³. Continued research and clinical trials are needed to refine these therapies and develop more personalized strategies to enhance patient survival and quality of life.Role of Bioinformatics in CRC ResearchBioinformatics, the intersection of biology, computer science, and information technology, has played a pivotal role in the identification and validation of reliable biomarkers for colorectal cancer. These biomarkers, which can be genetic, epigenetic, or proteomic in nature, hold the potential to guide clinicians in decision-making, enabling them to match suitable therapeutic regimens to individual patient profiles ¹⁴. Recent research efforts have focused on uncovering novel molecular biomarkers that could aid in early diagnosis, the development of new therapeutic approaches, and the monitoring of patient progress ¹⁵.
The application of next-generation sequencing (NGS) technologies, combined with advanced bioinformatics tools, has significantly advanced our understanding of the complex genomic and epigenomic landscapes of colorectal cancer ¹⁶. Whole Genome Sequencing (WGS) provides a comprehensive view of the tumor genome, allowing for the identification of driver mutations and structural variations ¹⁷. RNA Sequencing (RNA-seq) is used to analyze gene expression patterns, revealing dysregulated pathways and potential therapeutic targets ¹⁸. Targeted Sequencing enables the investigation of specific genes and pathways implicated in colorectal cancer, facilitating personalized treatment approaches ¹⁹. These NGS-based methods, combined with advanced bioinformatics pipelines, have transformed our understanding of colorectal cancer biology, facilitating the identification of key driver mutations, signaling pathways, and molecular subtypes ¹⁶. This knowledge enables the development of targeted therapies and the personalization of treatment strategies, paving the way
for more precise diagnostics and improved patient outcomes ³.
Furthermore, bioinformatics plays a crucial role in the analysis, integration, and interpretation of the vast amounts of data generated by these high-throughput technologies ¹⁶. This data-driven approach allows for a deeper understanding of the underlying biology of colorectal cancer, paving the way for the development of more effective and individualized treatment strategies.
Bioinformatics uses computational tools to store, search, and analyze biological information. It is an extensive array of computational systems that are related to database design and construction, proteomics, gene detection, and expression data clustering for studying cancer and several other diseases ²⁰. Bioinformatics plays an important role in CRC research by combining comprehensive screening with various available biological data that will lead to significant advances in the understanding and treatment of the disease ²¹.Emerging Methods in BioinformaticsIt is an emerging method that affects Artificial intelligence (AI) and Machine Learning Algorithm (ML) to improve the applications of bioinformatics in cancer biology ^22,23. Advanced multi-omics techniques were a hallmark for the comprehension of the biological processes in human health and cancer, which combine diverse datasets from affected individuals, enhance our comprehension of CRC’s clinical and molecular characteristics ²⁴. The use of single omics, such as genomics and transcriptomics, revealed many genes for a better understanding of the genomic landscape of cancer ²⁵. Biomarker Discovery and Validation Repeated analysis of publicly available protein datasets remains a popular bioinformatics application in CRC research, aiding in biomarker discovery and validation. Researchers have provided proteomics data through resources like the Clinical Proteomic Tumor Analysis Consortium (PTAC) and the PRIDE database ²⁶. Early diagnosis of cancer holds potential for decreased death rate and speedy recovery. The cancer associated molecules are changed in terms of over or under expression when associated to normal cells and thus could use as biomarkers for drug repurposing and therapeutic designing. This information can be exploited for targeting of cancer specially in terms of selective personalized medicine designing ²⁷. Prognostic and diagnostic markers (MSI, BRAF and RAS), can screen the response of CRC patients against the therapy. Hence, it is crucial to identify novel biomarkers that are highly sensitive and specific for early detection of CRC and selection of the best treatment²⁸. Furthermore, integrative analysis has also identified the role of the THBS2 (Thrombospondin-2) gene in CRC. Studies have shown that THBS2 gene expression can suppress the tumor immunity through the HIF1A/Lactic Acid/GPR132 pathway, highlighting the importance of integrating transcriptomic and functional data to understand the molecular mechanism of CRC ²⁹.Bioinformatics Tools and DatabasesBioinformatics tools and databases are important for biomarker discovery and drug development for CRC (Table 1).The Cancer Genome Atlas (TCGA)The Cancer Genome Atlas (TCGA) Research Network has summarized and analyzed large numbers of human tumors to identify molecular deviations at the biomolecule levels such as DNA, RNA, and Protein etc. The resulting huge data provides a major chance to develop an assimilated picture of commonalities, variances and developing themes across tumor
lineages ³⁰.Gene Expression Omnibus (GEO)Another repository, The Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) is another international public database for NGS functional genomic data sets and high-throughput microarray that is submitted by the research community specifically working on cancer. The source supports the archiving of raw, processed and metadata which are cross linked, indexed and searchable ³¹.Human Protein Atlas (HPA)The Human Protein Atlas (HPA) is a comprehensive protein database that combines antibody-based proteomics and transcriptomics to map the spatial distribution of proteins in cells, tissues, and organs ^32,33.The project aims to create a map of protein expression patterns in normal and cancer tissues, including colorectal cancer (CRC) ³². The HPA provides insights into protein expression localization in CRC by analyzing tissue-specific expression at both the gene and protein levels ³⁴. The database includes over 11,200 unique proteins, corresponding to more than 50% of all human protein-encoding genes ³⁴. By integrating various OMICS technologies, the HPA helps identify protein biomarkers and potential therapeutic targets, contributing to a better understanding of human biology and disease mechanisms ³⁵.Catalog of Somatic Mutations in Cancer (COSMIC)The Catalogue of Somatic Mutations in Cancer (COSMIC) is a comprehensive database that provides detailed information about somatic mutations in human cancer, helping researchers identify recurrent mutations that may serve as biomarkers or therapeutic targets. COSMIC includes nearly 6 million coding mutations curated from over 1.4 million tumor samples, as well as data on non-coding mutations, gene fusions, and copy number variants ³⁶.Ingenuity Pathway Analysis (IPA)Tools like ‘Upstream Regulator Analysis’, ‘Mechanistic Networks’, ‘Causal Network Analysis’ and ‘Downstream Effects Analysis’ are implemented and available within Ingenuity Pathway Analysis (IPA, http://www.ingenuity.com). These are some other important tools for variant discovery in high throughput sequencing data, omics data analysis, gene or protein interaction mapping networks developing and exploiting gene expression profiles for CRC-specific biomarkers that enable detection of mutations and other genetic alterations in the CRC genome [37– 39].Integrated Tools for Cancer GenomicsIntegrated tools such as cBioPortal and the UCSC Xena Browser for Cancer Genomics enable visualization and analysis of large cancer genomics datasets, integrating diverse data sets such as mutations and mRNA expression to explore genetic variation and clinical associations in CRC ^40,41. The discovery of appropriate receptor proteins and drug agents is equally significant in the case of drug discovery and development for CRC. Researcher attempted to discover CRC causing molecular signatures as receptors and drug agents as inhibitors by using integrated statistics and bioinformatics approaches ⁴², they have leveraged these integrated statistics and bioinformatics approaches to discover molecular signatures associated with CRC, focusing on receptor proteins and potential drug agents asinhibitors, thereby advancing drug discovery and development efforts in this field.Key Regulators in CRCA network-based bioinformatics (NBB) approach was used to identify novel biomarkers and therapeutic targets for CRC. The study used data from multiple cohorts to construct a CRCspecific gene co-expression network. A main risk of precision medicine using immunotherapy is detecting the markers from immunotherapy-treated patients that can quickly predict the drug responses across the multiple CRC patient cohorts. By identifying highly connected modules between the networks, the researchers identified several key regulators including MYC and TP53, which are involved in the pathogenesis of CRC, suggesting these genes as potential therapeutic targets exercise ⁴³. Another study used integrated bioinformatics analysis (IBA) to identify key genes and pathways associated with CRC development. The study combined gene expression data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Several hub genes such as COL1A1, COL1A2, and FN1 were found to be significantly associated with overall survival in CRC patients. These genes were proposed as potential biomarkers for CRC ^28,44.Machine Learning Algorithms in CRC ResearchIn another study, MLA were applied to integrated multi-omics data to predict potential biomarkers and therapeutic targets for CRC. On the basis of available TCGA data, the researchers found out a panel of biomarkers with high predictive accuracy for CRC diagnosis ⁴⁵. In another research, TCGA data and metabolomic profiles, were studies and researchers identified a set of dysregulated genes and metabolites in CRC tissues. These dysregulated molecules can serve as possible targets that will help scientists to generate novel drugs for the treatment of CRC ⁴⁶. Hence, there is an vital need to detect mutual novel biomarkers and shared pathways between CRC and EC to recognize the common molecular mechanisms that underlie the pathogenesis of CRC and EC, which will be useful for further pathophysiological studies of the diseases ⁴⁷. With the fast growth of whole-genome sequencing data (WGS), assimilating, archiving, analyzing, and visualizing those data becomes acute. The researchers identified several genes with aberrant methylation patterns that correlated with altered expression levels in CRC tissues. One such gene, SFRP1, was found to be hyper methylated and downregulated in CRC, suggesting its potential as a biomarker for early detection and as a target for demethylation therapies ⁴⁸.Challenges and limitationsCancer research has advanced and progressed greatly in understanding the mechanism of disease and its association with bioinformatics tools. But these advancements come with some challenges and limitations which researcher faces on daily basis.Huge and Complex DataOne of the biggest challenges is managing the huge and complex data. Technologies such as NGS generate huge quantities of data that require significant computational resources to store, process, and analyze. This requires complex high-performance computer systems, which can be costly and unreachable to all research institutions, especially those with restricted resources
⁴⁹.HeterogeneityAnother major challenge is the heterogeneity of cancer. Tumors can show a wide range of genetic, epigenetic, and phenotypic variances, not only between different patients but also within the same patient with passage of time. These differences make it difficult to detect the key mutations that cause cancer and develop effective targeted therapies⁵⁰. Standards issues also present significant barriers ⁵¹.Complexity and variabilityInter-genomics can provide valuable insight into CRC pathogenesis and help scientists to identify novel therapeutic targets; and diagnostic and prognostic biomarkers but this approach comes with its own challenges. The complexity and variability of these datasets mean that need advanced computational tools and algorithms to deal with them. For many years, large data analytics have depended on High Performance Computing (HPC) for an effective analysis. Today data is increasing at a faster pace, so new sorts of HPC will be required to access generally unique and huge sizes of data ²⁹. Data quality remains another important barrier. The quality of inputs has an important impact on the accuracy and reliability of bioinformatics analysis. Although important, rigorous quality control methods do not completely eliminate the possibility of misinterpretation ⁵².
Availability and Usage of Bioinformatics Tools
There are also some challenges in the availability and usage of bioinformatics tools. Many of these approaches are inaccessible to scientists with basic expertise in wet-lab molecular biology because they require specified abilities in bioinformatics and computational biology. Interdisciplinary collaboration is essential in this case to fill this skills gap, but this can be difficult to develop and sustain. Consequently, life-science projects, which are normally different, huge and geographically dispersed, have created distinctive challenges for collaboration and training ⁵³.Privacy and Ethical IssuesPrivacy and ethical issues become important when working with genomic data. With the increase in data breaches, it is important but also challenging to assure the security and privacy of patient data⁵⁴. In a larger sense, the main challenge faced by bioinformatics are mostly associated to the deluged of unprocessed data and assemble information that results from research on the genome and its expression. Consider the genome as the raw code, or machine code, necessary for the production and functioning of living entities.Overcoming ChallengesThese challenges show that to completely utilize bioinformatics in cancer research, infrastructure, methods, and training in the field must be continuously improved. Integrated bioinformatics analysis has the potential to transform cancer diagnosis, prognosis, and treatment in the field of colorectal cancer (CRC) research. This strategy, which aims to maximize therapeutic efficacy, is a considerable divergence from the conventional one-size-fits-all method ⁵⁵.Liquid BiopsiesLiquid Biopsies (LBs) are receiving great attention as they are easy, quick and non-invasive approaches for CRC diagnosis. LBs is performed constantly for disease checkup and are likely to overcome the restrictions of tissue biopsies. Key bioinformatics tools and techniques play a crucial role in processing and interpreting the data generated from these samples. Next generation sequencing (NGS) platforms are commonly employed
to detect genetic alterations, enabling the identification of potential biomarkers and therapeutic targets ⁵⁶.Combining Bioinformatics with AI and MLThe rapid advancements in high-throughput technologies, such as next-generation sequencing and imaging platforms, have resulted in an exponential growth of biomedical data. This wealth of data presents an unprecedented opportunity to leverage the power of bioinformatics, machine learning, and artificial intelligence to uncover novel biomarkers for colon cancer, ultimately leading to improved early detection, personalized treatment, and enhanced patient outcomes ⁵⁷.The integration of bioinformatics tools with machine learning and artificial intelligence techniques has proven to be a potent approach in the field of colon cancer research. Bioinformatics techniques, such as genetic algorithm and Pearson’s correlation coefficient, have been instrumental in identifying metabolic biomarkers associated with colon cancer, including those impacting critical metabolic functions ⁵⁸. Moreover, the use of deep learning algorithms has enabled the accurate classification of colon cancer subtypes, leading to more personalized treatment strategies ⁵⁸. Similarly, the application of AI-based methods has shown great promise in the detection and diagnosis of colon cancer. Deep cancer learning models have demonstrated the ability to stratify patients into high-risk and low-risk groups, allowing for the tailoring of treatment regimens and improving overall survival rates ⁵⁹. This advanced decision-making capability can reduce the operational workload for healthcare professionals and enhance the timely management of the disease. Furthermore, combining bioinformatics with machine learning (ML) and artificial intelligence (AI) holds significant potential. AI, and in particular, ML, have advanced remarkably in recent years as it is a key tool to intelligently examine the data and to develop the corresponding real-world applications and is also being used much more frequently. Researchers can learn more about the pathophysiology of colorectal cancer by modeling the intricate relationships seen in biological systems. Through the identification of significant regulatory connections and pathways that facilitate the advancement of cancer, this methodology provides access to novel therapeutic approaches ⁶⁰.

Conclusion

Bioinformatics has emerged as a powerful tool in the fight against colorectal cancer (CRC), offering significant promise for improving patient outcomes. By enabling the identification and validation of reliable biomarkers, bioinformatics paves the way for personalized medicine approaches, where treatment strategies can be tailored to individual patient profiles. The integration of next-generation sequencing technologies with advanced bioinformatics tools has revolutionized our understanding of the complex molecular landscape of CRC. This knowledge is crucial for the development of targeted therapies and the design of more effective treatment regimens. However, challenges remain. The vast amount of data generated by these high-throughput technologies necessitates robust infrastructure and advanced computational resources for storage, analysis, and interpretation. Additionally, tumor heterogeneity presents a significant hurdle, as genetic and phenotypic variations can complicate the identification of key driver mutations and the development of universally effective therapies. Despite these challenges, the future of bioinformatics in CRC research is bright. Continued advancements in artificial intelligence (AI) and machine learning (ML) hold immense potential for unlocking new insights from complex datasets. Integrating bioinformatics with AI and ML will further accelerate biomarker discovery, treatment personalization, and ultimately, improved survival rates for CRC patients. By overcoming current hurdles and embracing innovative technologies, bioinformatics will play a pivotal role in transforming CRC diagnosis, prognosis, and treatment in the years to come.

References

1. Cohen JD, Diergaarde B, Papadopoulos N, Kinzler KW, Schoen RE. Tumor DNA as a cancer biomarker through the lens of colorectal neoplasia. Cancer Epidemiol Biomarkers Prev. 2020;29(12):2441-2453.
   PubMed · Google Scholar
2. Lech G, Slotwinski R, Krasnodebski IW. The role of tumor markers and biomarkers in colorectal cancer. Neoplasma. 2014;61(01):1-8.
   PubMed · Google Scholar
3. Lu DY. Individualized cancer chemotherapy by detecting cancer biomarkers. J Postgenomics Drug & Biomark Dev. 2012;02(05):e121.
   PubMed · Google Scholar
4. Xie L, Wang L, Zhu W, Zhao J, Guo X. Editorial: Bioinformatics tools (and web server) for cancer biomarker development. Front Oncol. 2020;10:599085.
   PubMed · Google Scholar
5. Chavda V, Anand K, Apostolopoulos V. Bioinformatics tools for pharmaceutical drug product development. Bioinforma Tools Pharm Drug Prod Dev. 2023:1-421.
   PubMed · Google Scholar
6. Uchikov P, Khalid U, Kraev K, Hristov B, Kraeva M, Tenchev T, et al. Artificial Intelligence in the Diagnosis of Colorectal Cancer: A Literature Review. Diagnostics. 2024;14(5):528.
   PubMed · Google Scholar
7. Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5(1):22.
   PubMed · Google Scholar
8. Ooki A, Shinozaki E, Yamaguchi K. Immunotherapy in colorectal cancer: Current and future strategies. J anus, rectum colon. 2021;5(1):11-24.
   PubMed · Google Scholar
9. Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Neil H Segal NH et al. Immunotherapy in colorectal cancer: Rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361-375.
   PubMed · Google Scholar
10. Corrias G, Lai E, Ziranu P, Mariani S, Donisi C, Liscia N, et al. Prediction of response to anti-angiogenic treatment for advanced colorectal cancer patients: From biological factors to functional imaging. Cancers (Basel). 2024;16(7):1364.
    PubMed · Google Scholar
11. Salva de Torres C, Baraibar I, Saoudi González N, Ros J, Salva F, Rodríguez Castells M, et al. Current and emerging treatment paradigms in colorectal cancer: Integrating hallmarks of cancer. Int J Mol Sci. 2024;25(13):6967.
    PubMed · Google Scholar
12. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337-345.
    PubMed · Google Scholar
13. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch repair deficiency. J Clin Oncol. 2015;33(15_suppl):LBA100–LBA100.
    PubMed · Google Scholar
14. Kraus S, Nabiochtchikov I, Shapira S, Arber N. Recent advances in personalized colorectal cancer research. Cancer Lett. 2014;347(1):15-21.
    PubMed · Google Scholar
15. Aghagolzadeh P, Radpour R. New trends in molecular and cellular biomarker discovery for colorectal cancer. World J Gastroenterol. 2016;22(25):5678-5693.
    PubMed · Google Scholar
16. Shyr D, Liu Q. Next generation sequencing in cancer research and clinical application. Biol Proced Online. 2013;15(1):4.
    PubMed · Google Scholar
17. Del Vecchio F, Mastroiaco V, Di Marco A, Compagnoni C, Capece D, Zazzeroni F, et al. Next-generation sequencing: Recent applications to the analysis of colorectal cancer. J Transl Med. 2017;15:1-19.
    PubMed · Google Scholar
18. Bayle A, Basile D, Garinet S, Rance B, Laurent-Puig P, Blons H, et al. Next generation sequencing targeted panel in routine care for metastatic colon cancers. Cancers (Basel). 2021;13(22):5750.
    PubMed · Google Scholar
19. Koboldt DC, Steinberg KM, Larson DE, Wilson RK, Mardis ER. The next-generation sequencing revolution and its impact on genomics. Cell. 2013;155(1):27-38.
    PubMed · Google Scholar
20. Al-Zahrani MH. Colorectal cancer biomarkers discovery approach: A proteomic and genomic perspective. J Biochem Technol. 2023;14(3-2023):6-12.
    PubMed · Google Scholar
21. Chen W, Gao C, Liu Y, Wen Y, Hong X, Huang Z. Bioinformatics analysis of prognostic mirna signature and potential critical genes in colon cancer. Front Genet. 2020;11:478.
    PubMed · Google Scholar
22. Kourou K, Exarchos TP, Exarchos KP, Karamouzis M V, Fotiadis DI. Machine learning applications in cancer prognosis and prediction. Comput Struct Biotechnol J. 2015;13:8-17.
    PubMed · Google Scholar
23. Esteva A, Robicquet A, Ramsundar B, Kuleshov V, DePristo M, Chou K, et al. A guide to deep learning in healthcare. Nat Med. 2019;25(1):24-29.
    PubMed · Google Scholar
24. Hoadley KA, Yau C, Wolf DM, Cherniack A, Tamborero D, Ng S, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014;158(4):929-944.
    PubMed · Google Scholar
25. Chakraborty S, Sharma G, Karmakar S, Banerjee S. Multi-OMICS approaches in cancer biology: New era in cancer therapy. Biochim Biophys Acta Mol Basis Dis. 2024;1870(5):167120.
    PubMed · Google Scholar
26. Robles J, Prakash A, Vizcaíno JA, Casal JI. Integrated meta-analysis of colorectal cancer public proteomic datasets for biomarker discovery and validation. PLoS Comput Biol. 2024;20(1):e1011828-e1011828.
    PubMed · Google Scholar
27. Qi Y, Qi H, Liu Z, He P, Li B. Bioinformatics analysis of key genes and pathways in colorectal cancer. J Comput Biol. 2019;26(4):364-375.
    PubMed · Google Scholar
28. Dai GP, Wang LP, Wen YQ, Ren XQ, Zuo SG. Identification of key genes for predicting colorectal cancer prognosis by integrated bioinformatics analysis. Oncol Lett. 2020;19(1):388-398.
    PubMed · Google Scholar
29. Liu Y, Jiang C, Xu C, Gu L. Systematic analysis of integrated bioinformatics to identify upregulated THBS2 expression in colorectal cancer cells inhibiting tumour immunity through the HIF1A/Lactic Acid/GPR132 pathway. Cancer Cell Int. 2023;23(1):253.
    PubMed · Google Scholar
30. Network CGAR, Weinstein JN, Collisson EA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013;45(10):1113-1120.
    PubMed · Google Scholar
31. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: Archive for functional genomics data sets--update. Nucleic Acids Res. 2013;41(Database issue):D991-D995.
    PubMed · Google Scholar
32. Digre A, Lindskog C. The human protein atlas—spatial localization of the human proteome in health and disease. Protein Sci. 2021;30(1):218-233.
    PubMed · Google Scholar
33. Pontén F, Schwenk JM, Asplund A, Edqvist P. The Human Protein Atlas as a proteomic resource for biomarker discovery. J Intern Med. 2011;270(5):428-446.
    PubMed · Google Scholar
34. Pontén F, Jirström K, Uhlen M. The Human Protein Atlas—a tool for pathology. J Pathol A J Pathol Soc Gt Britain Irel. 2008;216(4):387-393.
    PubMed · Google Scholar
35. Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Tissue-based map of the human proteome. Science (80- ). 2015;347(6220).
    PubMed · Google Scholar
36. Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, et al. COSMIC: Somatic cancer genetics at high-resolution. Nucleic Acids Res. 2017;45(D1):D777-D783.
    PubMed · Google Scholar
37. Krämer A, Green J, Pollard Jr J, Tugendreich S. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics. 2014;30(4):523-530.
    PubMed · Google Scholar
38. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: A MapReduce framework for analyzing next generation DNA sequencing data. Genome Res. 2010;20(9):1297-1303.
    PubMed · Google Scholar
39. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6(1):1-6.
    PubMed · Google Scholar
40. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401-404.
    PubMed · Google Scholar
41. Goldman MJ, Craft B, Hastie M, Repečka K , McDade F, Kamath A, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675-678.
    PubMed · Google Scholar
42. Horaira MA, Islam MA, Kibria MK, Alam MJ, Kabir SR, Mollah MNH. Bioinformatics screening of colorectal-cancer causing molecular signatures through gene expression profiles to discover therapeutic targets and candidate agents. BMC Med Genomics. 2023;16(1):64.
    PubMed · Google Scholar
43. Kumar R, Mahmoud MM, Tashkandi HM, Haque S, Harakeh S, Ponnusamy K, et al. Combinatorial Network of Transcriptional and miRNA Regulation in Colorectal Cancer. Int J Mol Sci. 2023;24(6):5356.
    PubMed · Google Scholar
44. Hosseini ST, Nemati F. Identification of GUCA2A and COL3A1 as prognostic biomarkers in colorectal cancer by integrating analysis of RNA-Seq data and qRT-PCR validation. Sci Rep. 2023;13(1):17086.
    PubMed · Google Scholar
45. Arjmand B, Hamidpour SK, Tayanloo-Beik A, Arjmand B, Hamidpour SK, Tayanloo-Beik A, et al. Machine learning: A new prospect in multi-omics data analysis of cancer. Front Genet. 2022;13:824451.
    PubMed · Google Scholar
46. Bathe OF, Farshidfar F. From genotype to functional phenotype: Unraveling the metabolomic features of colorectal cancer. Genes (Basel). 2014;5(3):536-560.
    PubMed · Google Scholar
47. Zhang H, Dong S, Feng J. Epigenetic profiling and mRNA expression reveal candidate genes as biomarkers for colorectal cancer. J Cell Biochem. 2019;120(6):10767-10776.
    PubMed · Google Scholar
48. Silva TD, Vidigal VM, Felipe AV, DE Lima JM, Neto RA, Saad SS, et al. DNA methylation as an epigenetic biomarker in colorectal cancer. Oncol Lett. 2013;6(6):1687-1692.
    PubMed · Google Scholar
49. Stein LD. The case for cloud computing in genome informatics. Genome Biol. 2010;11(5):207.
    PubMed · Google Scholar
50. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013;501(7467):338-345.
    PubMed · Google Scholar
51. Baker M. 1,500 scientists lift the lid on reproducibility. Nature. 2016;533(7604):452-454.
    PubMed · Google Scholar
52. Guo Y, Zhao S, Sheng Q, Guo M, Lehmann B, Pietenpol J, et al. RNAseq by Total RNA Library Identifies Additional RNAs Compared to Poly(A) RNA Library. Biomed Res Int. 2015;2015:862130.
    PubMed · Google Scholar
53. MMangul S, Mosqueiro T, Abdill RJ, Duong D, Mitchell K, Sarwal V, et al. Challenges and recommendations to improve the installability and archival stability of omics computational tools. PLoS Biol. 2019;17(6):e3000333-e3000333.
    PubMed · Google Scholar
54. Gymrek M, McGuire AL, Golan D, Halperin E, Erlich Y. Identifying personal genomes by surname inference. Science (80- ). 2013;339(6117):321-324.
    PubMed · Google Scholar
55. Aran D, Sirota M, Butte AJ. Systematic pan-cancer analysis of tumour purity. Nat Commun. 2015;6:8971.
    PubMed · Google Scholar
56. Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: Towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223-238.
    PubMed · Google Scholar
57. Filipp F V. Opportunities for artificial intelligence in advancing precision medicine. Curr Genet Med Rep. 2019;7(4):208-213.
    PubMed · Google Scholar
58. Patel SK, George B, Rai V. Artificial intelligence to decode cancer mechanism: Beyond Patient stratification for precision oncology. Front Pharmacol. 2020;11:1177.
    PubMed · Google Scholar
59. Alabi RO, Bello IO, Youssef O, Elmusrati M, Mäkitie AA, Almangush A. Utilizing deep machine learning for prognostication of oral squamous Cell carcinoma-a systematic review. Front oral Heal. 2021;2:686863.
    PubMed · Google Scholar
60. Kitano H. A robustness-based approach to systems-oriented drug design. Nat Rev Drug Discov. 2007;6(3):202-210.
    PubMed · Google Scholar

Tables

Additional Information

Publisher’s Note
Bayrakol MP remains neutral with regard to jurisdictional and institutional claims.

Rights and Permissions

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). To view a copy of the license, visit https://creativecommons.org/licenses/by-nc/4.0/

View full license details →